Jupiter Endovascular Secures Over $40M, Advances Revolutionary Catheter Technology
October 14, 2025, 3:31 am
Jupiter Endovascular secured over $40M in Series B funding. This capital fuels development and commercialization of its TFX catheter platform. This innovative system brings unprecedented stability and control to complex endovascular procedures. It recently gained FDA 510(k) clearance. The technology addresses significant unmet needs in cardiovascular medicine. Initial applications target pulmonary embolism. Plans include expanding into other high-need areas. This funding round solidifies its position in advanced MedTech. The company is set to transform patient care.
Menlo Park, California. A medical technology startup, Jupiter Endovascular, has closed a Series B funding round. The company raised over $40 million. This significant investment accelerates the development and launch of its TFX catheter platform. The innovative system promises a new era in complex cardiovascular interventions. It targets critical unmet needs in patient care.
This funding solidifies Jupiter Endovascular's market position. It empowers the company to push boundaries in endovascular therapy. The TFX platform is a proprietary technology. It provides enhanced stability and control. This makes challenging procedures safer and more effective. Physicians gain a crucial tool for intricate anatomies.
Sonder Capital spearheaded the investment round. Other notable participants included Senvest Management and LB Investment. A new corporate investor also joined. The exact amount raised remains undisclosed. However, the over $40 million figure signifies strong investor confidence. It reflects the platform's potential impact.
The TFX platform is part of Jupiter’s Vertex Catheter system. This system recently secured 510(k) clearance from the FDA. This regulatory milestone permits legal marketing of the device in the United States. FDA clearance underscores the platform's safety and effectiveness. It paves the way for commercialization.
Funds from the Series B round serve multiple strategic objectives. Jupiter Endovascular will complete its ongoing SPIRARE II pivotal clinical trial. This trial is crucial for validating the TFX platform's performance. The capital also supports commercialization preparations. It allows for expanding into new clinical applications.
The company's initial focus targets pulmonary embolism. This life-threatening condition involves blood clots in the lungs. Current endovascular systems often struggle with precision in these delicate areas. The TFX platform offers a solution. It brings stability and anatomical protection to these procedures. This improves outcomes for patients.
Jupiter Endovascular envisions broader applications. The company plans to expand into additional high-need cardiovascular areas. This includes complex structural heart disease and peripheral artery disease. The TFX technology is versatile. Its ability to provide stable access across various anatomies holds immense promise.
Conventional endovascular systems face limitations. They struggle to reach certain areas safely or easily. This restricts treatment options for many patients. The TFX platform overcomes these barriers. It offers unprecedented control. This allows practitioners to navigate challenging vasculature with greater confidence.
The technology’s core innovation lies in its "Transforming Fixation." This mechanism enhances device stability during procedures. It minimizes unwanted catheter movement. This leads to more precise delivery of therapies. It reduces procedural risks and improves efficacy.
Jupiter Endovascular emerged as a spin-off from Neptune Medical. The company was founded in August 2024. It received $21 million in seed funding. This initial capital came from Neptune Medical’s $97 million Series D venture round. This history demonstrates a strong foundation in medical device innovation.
The chief executive, Carl J. St. Bernard, leads Jupiter Endovascular. The team is dedicated to addressing critical unmet needs. Their mission centers on improving precision and control. Catheter-based therapies stand to benefit greatly. The company’s trajectory is rapidly ascending.
Physicians face significant challenges. Operating in complex cardiovascular anatomies demands extreme precision. The lack of stability and control is a major hurdle. The TFX platform directly addresses this problem. It empowers clinicians with superior tools. This translates to better patient care.
First-in-human trial results are forthcoming. Jupiter Endovascular will present these findings. The Transcatheter Cardiovascular Therapeutics Conference in San Francisco is the venue. These presentations will showcase the real-world impact of the TFX system. They will highlight its clinical benefits.
The MedTech industry watches closely. Jupiter Endovascular represents a significant advancement. Its technology could redefine standards of care. Precision medicine is the future. This platform contributes directly to that vision. It offers solutions where none existed before.
This funding round strengthens Jupiter Endovascular’s research and development. It enables accelerated product cycles. New iterations and applications are on the horizon. The company's commitment to innovation remains steadfast. It continually seeks to refine and expand its offerings.
The MedTech landscape demands constant evolution. Jupiter Endovascular demonstrates this principle. Its TFX platform offers a transformative approach. It addresses critical clinical challenges. The company is poised for substantial growth. Its impact on cardiovascular health will be profound.
This funding secures Jupiter Endovascular’s future trajectory. It ensures the continued development of life-saving technologies. The focus remains on patient outcomes. Improved stability and control are not just technical achievements. They are pathways to better health. The journey has just begun.
Menlo Park, California. A medical technology startup, Jupiter Endovascular, has closed a Series B funding round. The company raised over $40 million. This significant investment accelerates the development and launch of its TFX catheter platform. The innovative system promises a new era in complex cardiovascular interventions. It targets critical unmet needs in patient care.
This funding solidifies Jupiter Endovascular's market position. It empowers the company to push boundaries in endovascular therapy. The TFX platform is a proprietary technology. It provides enhanced stability and control. This makes challenging procedures safer and more effective. Physicians gain a crucial tool for intricate anatomies.
Sonder Capital spearheaded the investment round. Other notable participants included Senvest Management and LB Investment. A new corporate investor also joined. The exact amount raised remains undisclosed. However, the over $40 million figure signifies strong investor confidence. It reflects the platform's potential impact.
The TFX platform is part of Jupiter’s Vertex Catheter system. This system recently secured 510(k) clearance from the FDA. This regulatory milestone permits legal marketing of the device in the United States. FDA clearance underscores the platform's safety and effectiveness. It paves the way for commercialization.
Funds from the Series B round serve multiple strategic objectives. Jupiter Endovascular will complete its ongoing SPIRARE II pivotal clinical trial. This trial is crucial for validating the TFX platform's performance. The capital also supports commercialization preparations. It allows for expanding into new clinical applications.
The company's initial focus targets pulmonary embolism. This life-threatening condition involves blood clots in the lungs. Current endovascular systems often struggle with precision in these delicate areas. The TFX platform offers a solution. It brings stability and anatomical protection to these procedures. This improves outcomes for patients.
Jupiter Endovascular envisions broader applications. The company plans to expand into additional high-need cardiovascular areas. This includes complex structural heart disease and peripheral artery disease. The TFX technology is versatile. Its ability to provide stable access across various anatomies holds immense promise.
Conventional endovascular systems face limitations. They struggle to reach certain areas safely or easily. This restricts treatment options for many patients. The TFX platform overcomes these barriers. It offers unprecedented control. This allows practitioners to navigate challenging vasculature with greater confidence.
The technology’s core innovation lies in its "Transforming Fixation." This mechanism enhances device stability during procedures. It minimizes unwanted catheter movement. This leads to more precise delivery of therapies. It reduces procedural risks and improves efficacy.
Jupiter Endovascular emerged as a spin-off from Neptune Medical. The company was founded in August 2024. It received $21 million in seed funding. This initial capital came from Neptune Medical’s $97 million Series D venture round. This history demonstrates a strong foundation in medical device innovation.
The chief executive, Carl J. St. Bernard, leads Jupiter Endovascular. The team is dedicated to addressing critical unmet needs. Their mission centers on improving precision and control. Catheter-based therapies stand to benefit greatly. The company’s trajectory is rapidly ascending.
Physicians face significant challenges. Operating in complex cardiovascular anatomies demands extreme precision. The lack of stability and control is a major hurdle. The TFX platform directly addresses this problem. It empowers clinicians with superior tools. This translates to better patient care.
First-in-human trial results are forthcoming. Jupiter Endovascular will present these findings. The Transcatheter Cardiovascular Therapeutics Conference in San Francisco is the venue. These presentations will showcase the real-world impact of the TFX system. They will highlight its clinical benefits.
The MedTech industry watches closely. Jupiter Endovascular represents a significant advancement. Its technology could redefine standards of care. Precision medicine is the future. This platform contributes directly to that vision. It offers solutions where none existed before.
This funding round strengthens Jupiter Endovascular’s research and development. It enables accelerated product cycles. New iterations and applications are on the horizon. The company's commitment to innovation remains steadfast. It continually seeks to refine and expand its offerings.
The MedTech landscape demands constant evolution. Jupiter Endovascular demonstrates this principle. Its TFX platform offers a transformative approach. It addresses critical clinical challenges. The company is poised for substantial growth. Its impact on cardiovascular health will be profound.
This funding secures Jupiter Endovascular’s future trajectory. It ensures the continued development of life-saving technologies. The focus remains on patient outcomes. Improved stability and control are not just technical achievements. They are pathways to better health. The journey has just begun.